Neonatal alloimmune thrombocytopenic purpura associated with a new platelet-specific alloantigen Pen' has been reported. We now provide direct evidence that the Pen' determinant is associated with glycoprotein (GP) IIIa, but that it is distinct from epitopes that define the pIA system. By ELISA wherein monoclonal antibodies specific for GPIIb (Tab) 
Introduction
Friedman and Aster (1) reported a new platelet-specific alloantigen designated Pen3 that has been implicated in at least two cases of neonatal alloimmune thrombocytopenic purpura (NATP) .' The entire family of the proband is positive for plA1, PiEl, and Bak3, and the proband herself is positive for plAl and 1 . Abbreviations used in this paper: GEL, gelatin; IPB, immunoprecipitation buffer; NATP, neonatal alloimmune thrombocytopenic purpura; PBS-TW, 67 mM PBS, pH 7.5, containing 0.15 M NaCl and 0.05% Tween 20; PTP, posttransfusion purpura; RCD, Ringer's citrate-dextrose; TG, 0.038 M Tris and 0.1 M glycine, pH 8.7. PiEl, but negative for Baka. Antibody in serum of the proband does not react with any previously recognized platelet-specific alloantigens, including plAl, p1E2, and Baka. The antibody reacted with 300 of 301 normal platelet preparations tested, but not with her own platelets or those from a patient with Glanzmann's thrombasthenia, deficient in platelet membrane glycoproteins (GP) IIb and IIIa. The single normal, unrelated platelet donor (Tru) nonreactive with anti-Pena was herself sensitized against Pena through blood (platelet) transfusion and thus produced the second antiserum recognized as specific for Pen3 (2) .
The GPIIb-IIIa complex is known to mediate platelet cohesion in concert with fibrinogen and calcium (reviewed in reference 3) and to carry target antigens for auto (4) (5) (6) , allo (7, 8) , and isoantibodies (9, 10) . Four platelet-specific alloantigen systems have been defined, plA, P1E, Ko, and Bak (Lek) (reviewed in reference 1 1). Among these alloantigens, pIA' and Bak' are those most often implicated in the etiology of posttransfusion purpura (PTP) and NATP (12) , and have been localized to GPIIIa and GPIIb, respectively (7, 8) . We now provide evidence that the alloantigen Pen', a causative factor in both NATP and PTP, is also associated with GPIIIa, but is an epitope distinct from P1A.
Methods
Antibodies. The antibodies reactive with the Pen3 alloantigen used in this study were from the proband studied by Friedman and Aster (1) and from a second patient with PTP due to anti-Pen' (2) . Antisera reactive with the Yuk3 and Yuk" allelic platelet alloantigens (13, 14) were a generous gift from Dr. Y. Shibata (Department of Immunohematology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan). All antisera and plasmas were heat inactivated (56'C for 30 min) before use. Preliminary studies indicate that Pen and Yuk are identical alloantigen systems, such that Pen3 is equivalent to Yukb, whereas Penb is identical to Yuk3 (Aster, R. H., and Y. Shibata, unpublished observations). By the antigen-capture ELISA described below, platelets from the proband as well as patient Tru were reactive with anti-Yuka (anti-Penb) but not with anti-Yuk" (anti-Pen').
The murine monoclonal antibodies, APl (specific for GPIba) (15), AP2 (specific for the GPIIb-GPIIIa complex) (16), AP3 (specific for GPIIIa) (17) , Tab (specific for GPIIb) (18) , and HB 43 (specific for the Fc portion ofhuman IgG) were isolated from ascites fluid as previously described (15, 16 , at a concentration of 1 mg/ml. 120 Al of the biotin solution was added to 1 ml of IgG, and the mixture was incubated at ambient temperature for 4 h. The reaction was terminated by dialysis of the reaction mixture against PBS, pH 7.5, containing 0.05% sodium azide.
Platelet isolation. 6 vol of whole blood were mixed with I vol of acid-citrate-dextrose (National Institutes of Health formula A) and centrifuged at 250 g for 12 min at ambient temperature to obtain PRP. PGE, (Sigma Chemical Co., St. Louis, MO) was added to the PRP to a final concentration of 20 ng/ml. After a 15-min incubation, the mixture was centrifuged at 750 g for 12 min to sediment the platelets. The platelet pellet was resuspended in Ringer's citrate-dextrose (RCD) buffer, pH 6.5, (20) containing 20 ng/ml PGE, and washed three times in the same buffer. The final platelet concentration was determined electronically using a counter (Coulter Electronics, Inc., Hialeah, FL).
Solubilization ofplatelets in Triton X-J00. Washed platelets were resuspended in nine parts of 0.038 M Tris and 0.1 M glycine, pH 8.7 (TG), mixed with one part of 10% (vol/vol) Triton X-l 0O in TG in the presence of 2.5 mM EDTA (to affect dissociation of GPIIb from GPIIIa), and agitated for 30 min at 4VC. Final platelet concentration was adjusted to 5 X 109/ml. The lysates were then centrifuged for 30 min (40C) at 80,000 g to pellet the insoluble material. The protein concentration of the supernatant was determined by the method of Markwell (21) and ranged from 8 to 10 mg/ml. The lysate was diluted 1:10 in TG containing 2.5 mM EDTA, and precleared of residual GPlIb-IIIa complexes by incubation with the complex-specific monoclonal antibody AP2 at ambient temperature overnight and by subsequent incubation with Protein A-Sepharose CL-4B at ambient temperature for 30 min. Preclearing in this fashion was performed to remove GPIIb-IIIa complexes from the lysate so that the only GPIIIa present would be the dissociated form. After centrifugation, the supernatant was further diluted 1:10 in TG containing 2.5 mM EDTA and then used as the source of soluble platelet antigens. By crossed immunoelectrophoresis, no precipitin arc characteristic of that given by the GPIIb-IIIa complex was detected in these precleared lysates (data not shown).
Purification ofGPIIIa. AP3 (3.5 mg) and nonimmune mouse IgG (5 mg) were coupled to 25 ml of Affi-Gel 10 (Bio-Rad Laboratories, Richmond, CA) according to the manufacturer's instructions.
Washed, pooled platelets (5 X 10") were solubilized in 50 mM TrisHCl, pH 7.5, containing 0.2 M NaCl, 0.4 mM phenylmethylsulphonyl fluoride, and 1% Triton X-100 and 10 mM EDTA at 4°C. After centrifugation at 100,000 g for 30 min, the lysate was precleared by incubation with nonimmune mouse IgG coupled to Affi-Gel 1O at ambient temperature for 60 min. The slurry was centrifuged at 1, 100 rpm for 10 min, and the supernatant was aspirated and then incubated with AP3 coupled to Affi-Gel 10 at 4°C overnight. The AP3-Affi-Gel 10 beads were then washed with Tris-HCl, pH 7.5, containing 0.5% Triton X-l00 and 1O mM EDTA, and GPIIIa was eluted by perfusion of the beads with 0.05 M diethanolamine buffer, pH 11.2, containing 0.02% SDS. The eluate was immediately neutralized with 0.5 M Tris-HCl, pH 6.8.
ELISA. 50 Al ofTab IgG or AP3 IgG in carbonate buffer, pH 9.6 at a concentration of 5 ,g/ml, were added to each well of a 96-well microtiter plate (Immulon I; Dynatech Laboratories, Inc., Alexandria, VA) and incubated at 4°C overnight. The wells were then filled with 67 mM PBS, pH 7.5, containing 0.15 M NaCl, 0.05% Tween 20, and 1% gelatin (PBS-TW-l% GEL), and incubated at ambient temperature for 30 min.
The microtiter plates were then washed twice with PBS-TW (same buffer minus GEL) using a Nunc Immunowash 12 apparatus (Vangard International Inc., Neptune, NJ) and incubated with the platelet lysate precleared of residual GPIIb-IIIa complex, as described above, containing 2.5 mM EDTA (50 ,l per well) at ambient temperature for 60 min. After three subsequent washes, 50 Al of anti-Pena, anti-PlA, antiBak', or control plasma, serially diluted in PBS-TW-0. 1% GEL, were added to duplicate or triplicate wells. The wells were washed three additional times, and biotinylated HB 43 diluted 1:500 in PBS-TW-0.1% GEL was added. The microtiter plates were then incubated at ambient temperature for 60 min, each well was washed an additional three times and incubated with avidin-biotin-alkaline phosphatase complex (Vectastain ABC-AP kit; Vector Laboratories, Inc., Burlingame, CA) diluted 1:250 in PBS-TW-0. 1% GEL for 15 min. After an additional four washes, substrate (p-nitrophenylphosphate) in 0.9 M diethanolamine buffer, pH 9.8, containing 0.5 mM MgCl2, was added, and the plates were incubated at 370C for 30 min. The absorbance at 405 nm was recorded using a microplate reader (MR 600; Dynatech Laboratories, Inc.). In the AP2-based antigen-capture ELISA, platelet lysates prepared in the absence of EDTA represented the source of GPIIb-GPIIIa complexes.
In selected experiments, purified GPIIIa from either homozygous PlAl-positive (Al/Al) or homozygous PlA'-negative (A2/A2) platelets was directly conjugated to microtiter wells. plA phenotype of donor platelets was determined independently by reactivity with anti-PlAl vs.
anti-PlA2 using both 5"Cr release and the AP2-based antigen-capture ELISA. 50 MAl of the respective, purified GPIIIa, diluted in carbonate buffer, pH 9.6, to a concentration of 2 Ag/ml, was added to each well of the microtiter plates and incubated at 4°C overnight. Antigen-coated plates were then blocked and washed in preparation for ELISA as described above.
Radioimmunoprecipitation. Washed platelets were radiolabeled with '25I by the lactoperoxidase-catalyzed method of Phillips and Poh Agin (22) were mixed with 25 Ml of normal human plasma. After a 1-h incubation at ambient temperature, 25 Ml of a 1:1 slurry of Protein A-Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) in IPB was added, and the mixture was incubated for 30 min. After centrifugation at 750 g for 3 min, the supernatant was obtained and used as the source of antigens. 25 Al of plasma containing anti-platelet alloantibody was added to 200 Ml of the antigen source (106 cpm), and the mixture was incubated at ambient temperature for 2 h with constant agitation. 25 Ml of Protein A-Sepharose CL-4B were then added, and the mixture was incubated an additional 30 min at ambient temperature. The Protein A beads were pelleted by centrifugation, washed three times with IPB, and then once more with IPB containing 0.2% SDS. Bound '251-labeled, platelet proteins were eluted by resuspending the final pellet in 50 Mul of SDS-PAGE sample buffer (2% SDS with or without 5% 2-mercaptoethanol) and incubating the mixture at 95-100°C for 5 min. The mixture was then centrifuged at 750 g for 5 min, and radiolabeled platelet proteins in the supernatant were analyzed by SDS-PAGE using a 7-15% exponential-gradient acrylamide gel. Gels were stained, destained, dried, and then exposed to Kodak XAR-5 film at -70°C for 5-7 d in the presence of image-intensifying screen (Cronex Hi-Plus; DuPont Co., Wilmington, DE).
Fluorocytometry
Platelets were obtained from EDTA-anticoagulated whole blood (0.3 ml of 5% EDTA per 10 ml blood) by differential centrifugation, washed three times in RCD, pH 6.5, containing 50 ng/ml PGEI and 
Quantitative indirect binding assay
Quantification of platelet-bound alloantibodies was performed according to a modification ofthe method ofLoBuglio et al. (23) . Briefly, 0.1 ml of PRP (2.5 X 108 platelets/ml) obtained from normal donors whose pIA and Bak phenotype is known was incubated with 0.1 ml of plasma containing alloantibody and 10 ,l (2 Mg) of 31'-labeled AP3 for 30 min at ambient temperature. The platelets were washed three times in 10 mM PBS, pH 6.5, containing 10 mM EDTA plus 50 ng/ml of PGEI and resuspended in 0.2 ml ofthe same buffer containing 1% BSA (PBS-BSA). 2 ,g ofpurified, '25I-labeled, murine monoclonal antibody specific for the Fc portion of human IgG (HB 43) in a volume of 0.05 ml was then added, and the mixture was incubated for an additional 30 min at ambient temperature.
PBS-BSA (0.25 ml) was then added, and 0.1 ml aliquots of this mixture were layered onto a 0.2-ml cushion of20% Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) in 0.4 ml soft polypropylene centrifuge tubes (Sarstedt, Inc., St. Louis, MO). The tubes were centrifuged at 10,000 g for 4 min in a centrifuge (Microfuge II; Beckman Instruments, Inc., Fullerton, CA). The tubes were then clamped with a hemostat at a point just above the platelet button, the tube tip was removed with a scalpel and placed in a glass tube, and the amount of radioactivity incorporated into the pellet was counted in a gamma scintillation counter. The number of molecules of radiolabeled probe bound to each target platelet was determined from the number of counts bound per platelet and the specific radioactivity (counts per minute/microgram protein) of the probe as described by LoBuglio et al. (23) . Platelet yield in the pellet was calculated from the recovery of '1ll-labeled AP3. Bound alloantibody per platelet was then recalculated based upon the determination of platelet recovery.
Inhibition ofADP-induced platelet aggregation PRP was obtained from freshly drawn whole blood anticoagulated with sodium citrate (1 ml of 3.8% sodium citrate per 9 ml whole blood). Various donors were selected who were known to be homozygous PlA'-positive (Al/Al), or homozygous PlA'-negative (A2/A2), or heterozygous for PIl" (A1/A2), but all positive for the Pen' allele. The platelet count was adjusted to 3 X 108/ml with autologous plateletpoor plasma. 300 ,ul of PRP was mixed with 100 ,l of normal, antiPen', or anti-PlAl plasma that was serially diluted in normal plasma, and the mixture was incubated at 37°C for 30 min. After addition of ADP (5 MM), the change in light transmission was recorded in a Lumi-aggregometer (Chrono-Log Corp., Havertown, PA) at 37°C with continuous stirring.
Results
ELISA. The monoclonal antibody-based, antigen-capture ELISA represents a straightforward way to determine the specificity of alloantibodies reactive with purified glycoprotein antigens. As shown in Fig. 1 A, anti-Pena and anti-PlAI IgG bound specifically to GPIIIa held by AP3, whereas anti-Bak' and control IgG did not. Conversely (Fig. 1 B) , anti-Bak' IgG bound specifically to GPIIb held by Tab, whereas anti-Pen8, anti-PlAl, and control IgG did not. The data presented in Fig. 1 is representative of four independent experiments.
Using this assay, lysates from all of 96 normal donors screened to date have been positive for anti-Pena but negative for anti-Yuk8 (Penb). Therefore, all ofthe platelet preparations used in the studies described below are considered to be homozygous Pena/Pena. In subsequent studies, GPIIIa purified from either PlAl-positive (A 1/Al) or PlA'-negative (A2/A2) platelets by AP3 immunoaffinity chromatography was directly conjugated to microtiter wells as antigen. As shown in Fig. 2 and B anti-PlA IgG bound specifically to PlAI-positive GPIIIa but not to PlAl-negative GPIIIa. On the other hand, anti-Pena reacted equally well with both PlA'-positive and PlA'-negative GPIIIa.
Radioimmunoprecipitation. Using the lactoperoxidase-catalyzed procedure, several platelet membrane proteins are radiolabeled with 125I, but GPIIb and GPIIIa incorporate a particularly high amount of the radioisotope (Fig. 3, lanes I and  5) . Both glycoproteins are readily detectable after SDS-PAGE and subsequent autoradiography. Using lysates derived from such radioiodinated platelets, anti-PlA' antibody precipitated a surface protein with electrophoretic characteristics, under re- Fluorocytometry. An estimate of the relative amount of human GPIIb and/or GPIIIa-specific antibodies bound per platelet at saturation was obtained by fluorocytometry. Using this method, we compared the binding of anti-PlA, anti-PlA2, anti-Pena, and a GPIIIa-specific isoantibody produced by a transfused patient with Glanzmann's thrombasthenia (OG IgG) (24) . OG IgG binds to GPIIIa but not to GPIIb in immunoblot assays using nonreduced protein (data not shown). In  Fig. 4 pectedly, when platelets typed homozygous for Pena were studied, the maximum amount of anti-Pena bound per platelet (17,300) was essentially one-half the maximum amount of platelet-bindable anti-PlA. Inhibition ofADP-induced platelet aggregation. All of the platelet preparations tested, including PlA-homozygous (A l/A 1), plA '-heterozygous (Al /A2), and PlA"-negative (A2/A2) platelets, were positive for Pena, and each aggregated to an equivalent extent in response to the addition of 5 gM ADP (Fig. 5 A) . Prior incubation with anti-PlA plasma at a 1:4 dilution completely inhibited aggregation of A 1/Al platelets, partially inhibited aggregation of A l/A2 platelets, but did not inhibit aggregation of A2/A2 platelets (Fig. 5 B) . The same findings were obtained with this source of anti-PlA at a dilution of 1:8. Each of numerous anti-PlAl plasmas tested inhibited aggregation at a final dilution characteristic ofthe amount of anti-PlAl activity detected in that plasma. However, regardless of the strength of the anti-PlAl plasma used, we only observed complete inhibition of platelet aggregation when platelets homozygous for plAl (Al/Al) were used. Anti-PlA1 could only partially inhibit aggregation of PlAl-heterozygous platelets, and in this case, the degree of residual aggregation was related more to the platelet source than the antibody source.
On the other hand, prior incubation with anti-Pena plasma at 1:4 dilution consistently inhibited platelet aggregation regardless of the PlA-phenotype of the platelets used (Fig. 5 C) . Identical inhibition was observed with a 1:8 dilution of this antiPena plasma.
Discussion
The Pen alloantigen system was first described by Friedman and Aster as the causative factor in a case of NATP (1) . Subsequently, one case of PTP associated with an antibody specific for the same antigen, Pena, was reported by Simon et al. (2) . Also, a recently reported platelet alloantigen system, Yuk, which was the causative factor of several cases of NATP in Japan (13, 14) has turned out to be identical to the Pen system (Aster, R. H., and Y. Shibata, unpublished observations In the presence of calcium ions, GPIIIa is complexed with GPIIb constituting a receptor site not only for fibrinogen (27) but also for fibronectin (28) (6) also reported autoantibodies against the GPIIb-IIIa complex in patients with the same disorder. Also, isoantibodies directed against components of the GPIIb-IIIa complex have been described in plasma from polytransfused patients with Glanzmann's thrombasthenia (9, 10, and this study). Pen (Yuk) represents the second platelet-specific alloantigen system localized to GPIIIa. In view of the important role of GPIIIa in both platelet physiology and platelet immunology, anti-Pena represents yet another valuable reagent for the further characterization of the structure, function, and antigenic makeup of this glycoprotein. In particular, if a previously unrecognized heterogeneity of the GPIIIa molecule exists that may be relevant to its function as a component of the physiologic receptor for platelet cohesion, anti-Pen antibodies can be used to establish and characterize this heterogeneity.
